Axsome Therapeutics: Morgan Stanley cuts target price to $223 from $249
AXSM•Morgan Stanley cut its target price for Axsome Therapeutics to $223 from $249.
Related News
Deutsche Bank offers up to USD 200 million in capital-protected certificates
DB•
Novo seeks FDA, EMA approval for once-daily sickle cell therapy etavopivat
NVO•
Netskope cut to equal-weight by Morgan Stanley, which raises price target to $24
NTSK•
Chinese AI shares tumble after Nvidia's Huang resigns
NVDA•
Prudential files next-day disclosure with HKEX announcing share buyback and cancellation
PUK•